India: Product Patenting in the Indian Pharma Sector

Last Updated: 14 June 2006
Article by Manisha Singh

In the recent times the Indian pharma sector has been marked by dynamic changes. The Patent Act of 1970 as amended on March 22, 2005 marked the end of a protected era and has brought in a new phase in the integration of India into the global pharmaceutical market. The new amendment further makes copying of post-1995 patented drugs illegal. At the same time the amendment granting product patents has been hailed to be opening vast opportunities to the Indian Pharmaceutical firms. A look at the sector shows that large companies like Ranbaxy, Nicholas Piramal, Dr Reddy's, Wockhardt, Lupin etc, have been investing heavily in R&D and are planning to launch their own-patented molecules all over the world. Wockhardt in order to bring innovative and advanced drugs in speciality areas to India, has signed an in-licensing agreement with Life Sciences Investment Limited (LSI), a UK based company, to market and produce Vitrix, a patented product for the treatment of vitiligo, a pigmentation disorder for which the active pharmaceutical ingredients shall be imported from LSI .

As India enters product patent regime the impact of such a move would definitely have on the Indian pharmaceutical industry, health care industry etc., and therefore the legal machinery enforcing these regulations demands attention. In the pharma sector today, according to studies, India produces 22% of the global generic market. It can be said that in the last decade, after liberalization, Indian industry has focused on the world market and brought about structural and fundamental changes, like investing in research and accessing global market.

The regulatory system focused mainly on process patents has helped to establish the foundation of a strong and highly competitive domestic pharmaceutical industry along with helping it to emerge into a world supplier of bulk drugs and medicines at affordable prices not only to common man in India and the developing world. Admittedly it cannot be overlooked that the introduction of product patents will, however bring forth significant changes and divides within the industry. It cannot be denied that the process patent helped the Indian Pharmaceutical Industry to flourish into a world-class generics industry but the product patent regime would turn out to be more favorable to players with built-in scientific and technical resources.

In this context a recent decision by the High Court of Madras can be discussed. In Wockhardt Ltd. v. Hetero Drugs Ltd. & Ors 2006 (32) PTC 65 (Mad.) (DB), the appellant was the holder of Process patent, Exclusive Marketing Rights and Drug License for the manufacture of pharmaceutical preparation namely, Nadifloxacin 1% cream. The first respondent had started manufacturing and selling the same product infringing the patent and EMR granted to the appellant. Appellant was already holding the Process Patent for an admixture compound. By 2002, the Appellant made an application for Product Patent, which was treated as a mail box application. In the mean time, the first respondent applied for manufacturing license to manufacture Nadifloxacin 1% cream by adopting US Patent 1981 and Japan Patent 1983 under the trademark Nadiderm. In 2004 the Drugs Controller General granted license to the respondents and they started manufacturing and selling Nadifloxacin 1% cream. The question arose as to who could be the manufacturer and as to whether the appellant in this case could claim exclusive right over the EMR and the process patent. According to the respondents, the appellants could not claim invention of the product, since the first respondent obtained manufacturing license for the impugned product from the Drug Controller General. As a regular marketing license of a drug is to be preceded by a trial-manufacturing license for the purpose of clinical trial, the first respondent had been manufacturing the impugned product prior to 2004 itself. Moreover the first respondent contended that they had followed only the process adopted by the US and Japanese Patents and hence, as such the appellants could not claim EMR and the Process Patent.

The court observed that the Patent Office had granted both Process Patent and EMR in favour of the appellant. The appellants had obtained Process Patent with effect from the date of application in 2000 and the appellant had also applied for Product Patent after the amendment of the Act. Further it held that EMR being a short-term arrangement the appellant would suffer irreparable damage because of elapse of that period. It granted injunction in favour of the appellant, thus granting protection to the appellant’s exclusive rights for its product, the Nadifloxacin 1% cream. The case thereby proves the liberal approach and the bent of mind of the court towards products patent.

© Lex Orbis 2006

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions